Supplementary Table 4: Summary of discussed studies on biomarkers for treatment response in the period 2012–2015 biomarker Clinical purpose Cohorts of the Novel information Cohort Remarks initial studies obtained in confirmation (diagnosis and studies (number of number of patients) patients) Anti-IFNβ Nab Response to IFNβ1 Numerous studies, Numerous studies, RRMS n = 1642 IFNβ-Abs are early reviewed by Polman lack novelty to RRMS n = 2773 predictors Nab et al.1 previous published RRMS n = 1184 MxA miRNA work correlated to disability progression in IFNβ treatment Antibody dissociation rates predict persistence of Nab Anti-natalizumab Response to RRMS n = 6255 Confirmation of initial RRMS n = 736 (Nab) natalizumab5 clinical purpose6,7 RRMS n = 1,3797 IL-17F Response to IFNβ8 RRMS n = 268 Initial findings RRMS n = 2399 confirmed only for very high levels9 miRNA Response to IFNβ Initial clinical RRMS n = 610 purpose10,11 RRMS n = 6011 Anti-JCV antibodies Predicting risk of PML n = 54 and Confirmation of initial PML n = 71 PML and PML12 n = 5,89612 clinical purpose13 non-PML n = 2,52213
Supplementary Table 4: Summary of discussed studies on biomarkers for treatment response in the period 2012–2015 biomarker Clinical purpose Cohorts of the initial studies (diagnosis and number of patients) Novel information obtained in Cohort confirmation studies (number of patients) Remarks Anti-IFNβ Nab Response to IFNβ1 Numerous studies, reviewed by Polman et al.1 Numerous studies, lack novelty to previous published work RRMS n = 1642 RRMS n = 2773 RRMS n = 1184 IFNβ-Abs are early predictors Nab MxA miRNA correlated to disability progression in IFNβ treatment Antibody dissociation rates predict persistence of Nab Anti-natalizumab (Nab) Response to natalizumab5 RRMS n = 6255 Confirmation of initial clinical purpose6,7 RRMS n = 736 RRMS n = 1,3797 IL-17F Response to IFNβ8 RRMS n = 268 Initial findings confirmed only for very high levels9 RRMS n = 2399 miRNA Response to IFNβ Initial clinical purpose10,11 RRMS n = 610 RRMS n = 6011 Anti-JCV antibodies Predicting risk of PML12 PML n = 54 and n = 5,89612 Confirmation of initial clinical purpose13 PML n = 71 PML and non-PML n = 2,52213
nrneurol.2015.173-s4.docx